1. Home
  2. ATOS vs ELDN Comparison

ATOS vs ELDN Comparison

Compare ATOS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$4.99

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$2.67

Market Cap

208.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATOS
ELDN
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.2M
208.6M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
ATOS
ELDN
Price
$4.99
$2.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$31.67
$8.50
AVG Volume (30 Days)
89.0K
913.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
16.67
54.27
EPS
N/A
N/A
Revenue
$1,758.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$1.35
52 Week High
$7.56
$4.60

Technical Indicators

Market Signals
Indicator
ATOS
ELDN
Relative Strength Index (RSI) 66.34 57.17
Support Level $0.68 $2.48
Resistance Level $5.12 $2.77
Average True Range (ATR) 0.35 0.21
MACD -0.06 0.01
Stochastic Oscillator 72.46 43.85

Price Performance

Historical Comparison
ATOS
ELDN

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: